GPP
CRBP icon

Great Point Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Great Point Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-20,000
Closed -$4.26M – 39
2017
Q4 		$4.26M Buy
+20,000
New +$4.28M 0.73% 31

Other funds holding CRBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Great Point Partners's CRBP Position: Q1 2018 in Review

Great Point Partners sold out of Corbus Pharmaceuticals (CRBP) in Q1 2018, closing a stake of 20,000 shares — an estimated $4.26M sold.

Great Point Partners first reported a position in CRBP in Q4 2017 and held it in 1 quarter. The position peaked at $4.26M in Q4 2017. 81 funds tracked by Wall St. Rank hold CRBP as of Q1 2018.

  • Great Point Partners reported no remaining Corbus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Great Point Partners sold 20,000 Corbus Pharmaceuticals shares in Q1 2018, an estimated $4.26M.
  • Great Point Partners first reported a position in Corbus Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Great Point Partners's Corbus Pharmaceuticals position peaked at $4.26M in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2018.

Based on Great Point Partners's 13F filing for Q1 2018, filed 14 May 2018.